| Revenue growth | 13% sequential growth; 9% YoY decline due to Librela absence. |
|---|---|
| Margins | EBITDA margins improved 6% QoQ to 18%; impacted by FX losses. |
| Order book | Signed first US biologics manufacturing contract for Bayview facility. |
| Demand visibility | Strong demand for biologics and CDMO; Discovery services seeing client attrition. |
| Management confidence | Cautiously optimistic; focusing on structural reorganization and cost optimization. |
Growth
Revenue grew 13% QoQ but fell 9% YoY; Discovery Services remains stable while CDMO is building a pipeline.
Outlook
Management maintains FY27 EBITDA margin guidance at mid-20s despite current H1 pressures.
Risks
YoY de-growth persists; foreign exchange hedge losses of ₹61 Cr impacted margins significantly this quarter.
Earnings Call Transcript filed with BSE, NSE: SYNGENE. Summary written with AI assistance from the document.
Syngene International Ltd: key numbers
- Share price
- ₹410.85
- Market cap
- ₹16,585 Cr
- Revenue (annual)
- ₹3,739 Cr
- Net profit (annual)
- ₹316.7 Cr
- P/E (TTM)
- 89.1×Sector 46.1×
- Promoter holding
- 52.59%+0.00% QoQ
- FII holding
- 10.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syngene International Ltd
All →Syngene International Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 833 Cr (down 9% YoY, up 13% QoQ). Operating EBITDA margin 18% on forex hedge losses. PAT before exceptionals Rs 38 Cr (down 44% YoY). Focus on integrated CRDMO and first Bayview biologics deal.
Syngene International Results Update
Syngene reported Q2 FY27 revenue of Rs 833 Crore, up 13% sequentially, with PAT of Rs 32 Crore. Release includes P&L highlights and business updates.
Syngene International Management Change
Syngene reports changes in senior management: two heads move from SMP to Non-SMP, Ajay Tandon resigns effective October 30, 2026, and CFO Deepak Jain plans to leave. The CFO is a KMP, so this is a material leadership change.
Syngene International Q2 FY27 Results: Net Profit ₹32.2 Cr, Down 52.0% YoY
Syngene International Ltd reported revenue from operations of ₹832.7 Cr (-8.6% YoY) and net profit of ₹32.2 Cr (-52.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹32.2 Cr · -52.0% YoY
Syngene International Other Announcement
Syngene International Limited has submitted the quarterly certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended September 30, 2026.
Syngene International Board Meeting Date
Syngene International Limited will hold a board meeting on October 27, 2026, to approve the standalone and consolidated financial results for the quarter ended September 30, 2026.